The 12-week U.S. Phase IIa study is evaluating the efficacy, safety and tolerability of the once-monthly subcutaneous (SQ) depot formulation (treatment formulation) of small molecule ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback